IUGNF.US Imugene Limited

Healthcare Biotechnology USA Stocks
0.0290 USD
Close of Nov 15, 2026
0.0100 0.2950
Market cap
USD 16.1M
P/E
-
P/B
2.61x
ROE
-1,169.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is IUGNF.US undervalued?

Graham number

The Graham number of Imugene Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Imugene Limited fundamental analysis

No fundamental analysis for Imugene Limited yet.

Imugene Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Imugene Limited

Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to gener…

Full company profile